. 2020 Aug 5;4(4):434–442. doi: 10.1016/j.mayocpiqo.2020.04.012

Table 1.

Details of the Randomized Clinical Trials

Study, year	N	Comparative treatment	Study period	Country	Follow-up (mo)	Population
Becker et al, 2005²⁵	760	Febuxostat 80 mg vs febuxostat 120 mg vs allopurinol	July 2002–February 2004	United States and Canada	12	Gout and hyperuricemia
Schumacher et al, 2008²³	1072	Febuxostat 80 mg vs febuxostat 120 mg vs febuxostat 240 mg vs allopurinol vs placebo	February 2003–April 2004	United States	6.4	Gout
Becker et al, 2009¹⁸	1086	Febuxostat 80 mg vs febuxostat 120 mg vs allopurinol	—	United States and Canada	40	Gout
Becker et al, 2010²⁴	2269	Febuxostat 40 mg vs febuxostat 80 mg vs allopurinol	—	United States	6	Gout
Huang et al, 2014²⁰	516	Febuxostat 40 mg vs febuxostat 80 mg vs allopurinol	February 2010–December 2010	China	6.4	Gout
Nagakomi et al, 2015²⁰	61	Febuxostat 40 mg vs allopurinol	September 2011–April 2013	Japan	12	Heart failure and hyperuricemia
Saag et al, 2016²²	96	Febuxostat 30 mg twice daily vs Febuxostat 40–80 mg once daily vs placebo	–	United States	12	Gout and chronic kidney disease
Dalbeth et al, 2017²⁶	314	Febuxostat 40–80 mg vs placebo	–	United States	24	Gout
Gunawardhana et al, 2017²⁸	121	Febuxostat 80 mg vs placebo	–	United States	1.5	Hypertension and hyperuricemia
Gunawardhana et al, 2018²⁷	189	Febuxostat IR 40 mg vs febuxostat XR 40 mg vs febuxostat IR 80 mg vs febuxostat XR 80 mg vs placebo	May 2014–October 2015	United States	3	Gout
Kimura et al, 2018³⁰	443	Febuxostat 10–40 mg vs placebo	November 2012–January 2014	Japan	25	Asymptomatic hyperuricemia and stage 3 chronic kidney disease
Mukri et al, 2018¹⁹	93	Febuxostat 40 mg vs placebo	—	Malaysia	6	Diabetic nephropathy (chronic kidney disease stage 3 and 4) and hyperuricemia
White et al, 2018⁹	6190	Febuxostat 40–80 mg vs allopurinol	April 2010–May 2017	United States	32	Gout and previous cardiovascular events
Kojima et al, 2019³¹	1070	Febuxostat 10–40 mg vs non-febuxostat group (allopurinol 100 mg given if serum uric acid was elevated)	November 2013–October 2014	Japan	36	Elderly patients aged ≥65 y with hyperuricemia (serum uric acid >7.0 to ≤9.0 mg/dL) who had one or more risks for cerebral, cardiovascular, or renal disease
Saag et al, 2019²¹	1790	Febuxostat IR 40 mg vs febuxostat XR 40 mg vs febuxostat IR 80 mg vs febuxostat XR 80 mg vs placebo	April 2015–November 2016	United States	3	Gout